Drug Profile
CDX 1140
Alternative Names: CDX-1140Latest Information Update: 27 Feb 2024
Price :
$50
*
At a glance
- Originator Celldex Therapeutics Inc
- Developer Albert Einstein College of Medicine; Celldex Therapeutics Inc; Merck & Co; University of Texas Southwestern Medical Center; Washington University School of Medicine
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action CD40 antigen stimulants; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Lymphoma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Pancreatic cancer; Solid tumours; Triple negative breast cancer
Most Recent Events
- 21 Nov 2023 Washington University School of Medicine, in collaboration with Celldex Therapeutics and The Foundation for Barnes-Jewish Hospital terminates a phase II trial in Pancreatic cancer (Combination therapy) in USA (IV; infusion) due to Celldex decision (NCT04536077)
- 23 Jun 2023 Albert Einstein College of Medicine and Celldex Therapeutics terminates phase I/II trials in Non-small cell lung cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in USA due to low accural (Parenteral) (NCT04491084)
- 09 Nov 2022 Discontinued - Phase-I for Lymphoma (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (Parenteral)